Clinical Trial

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Recruiting
View on ClinicalTrials.gov →
Summary
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-11-25; most recent amendment 2022-02-17.
Status change: Not Yet Recruiting → Recruiting 2020-02-11
Trial Details
NCT Number NCT04179929
Lead Sponsor PETHEMA Foundation
Conditions Acute Lymphoblastic Leukemia
Enrollment 300 participants
Start Date 2019-11-25
Primary Completion 2026-11 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2022-02-18